DR. KRISHNA SIVA SAI KAKKERA M.D
Prescription History 1831445261
Internal Medicine - Pulmonary Disease in Little Rock, AR

NPI Status: Active since August 03, 2012

Contact Information

10001 LILE DR
LITTLE ROCK, AR
ZIP 72205
Phone: (501) 552-0500

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. KRISHNA SIVA SAI KAKKERA M.D, an active Pulmonary Disease specialist practicing in Little Rock, AR. Our medical registry currently tracks 13 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 298 documented patient claims. Among these therapy options, the most frequently utilized medication is Symbicort, which accounts for 77 claims alone.


Albuterol Sulfate Hfa

Generic Formulation: Albuterol SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 39
30-Day Fills 46.3
Days Supply 1,195
AR State Average Benchmarks
Peer Average Claims70.0
Peer Average 30-Day Fills83.8
Peer Average Days Supply2,091
Conservative Utilization

This provider writes prescriptions for this formulation 44.3% less frequently than the standard regional baseline metric for practitioners inside AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,150.58 across this reporting matrix range.

Provider Avg Cost Per Claim

$29.50

State Avg Cost Per Claim

$47.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Anoro Ellipta

Generic Formulation: Umeclidinium Brm/Vilanterol TrSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 23.0
Days Supply 690
AR State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills34.4
Peer Average Days Supply1,029
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 53.6% less volume than the regional standard for practitioners inside AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $10,779.21 across this reporting matrix range.

Provider Avg Cost Per Claim

$829.17

State Avg Cost Per Claim

$580.15

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: umeclidinium and vilanterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Vilanterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Umeclidinium/vilanterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as vilanterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Breo Ellipta

Generic Formulation: Fluticasone/VilanterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
AR State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills38.4
Peer Average Days Supply1,149
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 61.3% less volume than the regional standard for practitioners inside AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,787.84 across this reporting matrix range.

Provider Avg Cost Per Claim

$398.99

State Avg Cost Per Claim

$501.64

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to prevent and decrease symptoms (wheezing and trouble breathing) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, including chronic bronchitis and emphysema). This inhaler contains 2 medications: fluticasone and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the swelling of the airways in the lungs to make breathing easier. Vilanterol belongs to a class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. When used alone, long-acting beta agonists (like vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Fluticasone Propionate

Generic Formulation: Fluticasone PropionateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 11
30-Day Fills 14.0
Days Supply 398
AR State Average Benchmarks
Peer Average Claims56.0
Peer Average 30-Day Fills84.8
Peer Average Days Supply2,534
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 80.4% less volume than the regional standard for practitioners inside AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $166.12 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.10

State Avg Cost Per Claim

$17.17

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Incruse Ellipta

Generic Formulation: Umeclidinium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
AR State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills27.6
Peer Average Days Supply825
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 52.2% less volume than the regional standard for practitioners inside AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,209.55 across this reporting matrix range.

Provider Avg Cost Per Claim

$382.69

State Avg Cost Per Claim

$451.56

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Umeclidinium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Ipratropium Bromide

Generic Formulation: Ipratropium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 15.7
Days Supply 438
AR State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills41.1
Peer Average Days Supply1,097
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 59.4% less volume than the regional standard for practitioners inside AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $560.25 across this reporting matrix range.

Provider Avg Cost Per Claim

$43.10

State Avg Cost Per Claim

$42.19

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A muscarinic antagonist structurally related to ATROPINE but often considered safer and more effective for inhalation use. It is used for various bronchial disorders, in rhinitis, and as an antiarrhythmic.

Therapeutic Applications

Ipratropium is used to control and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. For preventing symptoms of lung disease, this medication must be used regularly to be effective. Use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) for wheezing or sudden shortness of breath unless otherwise directed by your doctor. Ipratropium does not work as fast as your quick-relief inhaler, but may sometimes be used to relieve symptoms of wheezing or sudden shortness of breath if so prescribed by your doctor.

Montelukast Sodium

Generic Formulation: Montelukast SodiumSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 37
30-Day Fills 75.0
Days Supply 2,250
AR State Average Benchmarks
Peer Average Claims59.0
Peer Average 30-Day Fills112.6
Peer Average Days Supply3,350
Conservative Utilization

This provider writes prescriptions for this formulation 37.3% less frequently than the standard regional baseline metric for practitioners inside AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $343.99 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.30

State Avg Cost Per Claim

$18.27

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Montelukast is used to control and prevent symptoms caused by asthma (such as wheezing and shortness of breath). It is also used before exercise to prevent breathing problems during exercise (bronchospasm). This medication can help decrease the number of times you need to use your quick relief inhaler. Montelukast is also used to relieve symptoms of hay fever and allergic rhinitis (such as sneezing, stuffy/runny/itchy nose). Since there are other allergy medications that may be safer (see also Warning section), this medication should be used for this condition only when you cannot take other allergy medications or they do not work well. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks or breathing problems. If an asthma attack or sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This drug works by blocking certain natural substances (leukotrienes) that may cause or worsen asthma and allergies. It helps make breathing easier by reducing swelling (inflammation) in the airways.

Nucala

Generic Formulation: MepolizumabSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
AR State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills17.9
Peer Average Days Supply508
Conservative Utilization

This provider writes prescriptions for this formulation 29.4% less frequently than the standard regional baseline metric for practitioners inside AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $40,379.16 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,364.93

State Avg Cost Per Claim

$3,710.96

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used along with other medications to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you do your normal activities and decreases time lost from work or school. Mepolizumab is also used to treat certain other immune system disorders (chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome). This medication works by decreasing a certain type of white blood cell (eosinophils). This effect helps reduce swelling (inflammation) of the airways to make breathing easier. It may also help reduce the size of nasal polyps, and lessen symptoms such as runny/stuffy nose, mucus in the throat, loss of smell, facial pain, and tiredness. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks or breathing problems. If an asthma attack occurs, use your quick-relief inhaler as prescribed.

Prednisone

Generic Formulation: PrednisoneSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 201
AR State Average Benchmarks
Peer Average Claims50.0
Peer Average 30-Day Fills57.4
Peer Average Days Supply961
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 72.0% less volume than the regional standard for practitioners inside AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $81.93 across this reporting matrix range.

Provider Avg Cost Per Claim

$5.85

State Avg Cost Per Claim

$7.13

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Roflumilast

Generic Formulation: RoflumilastSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
AR State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills26.0
Peer Average Days Supply772
Conservative Utilization

This provider writes prescriptions for this formulation 36.8% less frequently than the standard regional baseline metric for practitioners inside AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,228.63 across this reporting matrix range.

Provider Avg Cost Per Claim

$102.39

State Avg Cost Per Claim

$264.39

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Roflumilast is used to control and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis). It should be used along with other medications (bronchodilators such as salmeterol, ipratropium) to treat COPD. It works by reducing the irritation and swelling of the airways. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath or wheezing. If sudden breathing problems occur, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Spiriva Handihaler

Generic Formulation: Tiotropium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
AR State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills26.6
Peer Average Days Supply797
Conservative Utilization

This provider writes prescriptions for this formulation 45.0% less frequently than the standard regional baseline metric for practitioners inside AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,892.62 across this reporting matrix range.

Provider Avg Cost Per Claim

$535.69

State Avg Cost Per Claim

$696.95

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A scopolamine derivative and CHOLINERGIC ANTAGONIST that functions as a BRONCHODILATOR AGENT. It is used in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

Tiotropium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Symbicort

Generic Formulation: Budesonide/Formoterol FumarateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 77
30-Day Fills 91.0
Days Supply 2,730
AR State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills43.1
Peer Average Days Supply1,291
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 133.3% higher than the standard regional baseline profile for AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $36,990.72 across this reporting matrix range.

Provider Avg Cost Per Claim

$480.40

State Avg Cost Per Claim

$507.81

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of budesonide and formoterol fumarate that is used as an ANTI-ASTHMATIC AGENT and for the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: budesonide and formoterol. Budesonide belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. Before using this medication, it is important to learn how to use it properly. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. See also How to Use section.

Trelegy Ellipta

Generic Formulation: Fluticasone/Umeclidin/VilanterSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 36
30-Day Fills 36.0
Days Supply 1,080
AR State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills58.2
Peer Average Days Supply1,742
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $24,995.96 across this reporting matrix range.

Provider Avg Cost Per Claim

$694.33

State Avg Cost Per Claim

$829.51

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 3 medications: fluticasone, umeclidinium, and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling of the airways in the lungs to make breathing easier. Umeclidinium belongs to a class of drugs known as anticholinergics and vilanterol is a LABA medication. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Both drugs are also known as bronchodilators. When used alone, long-acting beta agonists (such as vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination products containing both an inhaled corticosteroid and long-acting beta agonist, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with two asthma-control medications (such as inhaled corticosteroid and long-acting beta agonist) or if your symptoms need combination treatment. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. KRISHNA SIVA SAI KAKKERA M.D provides transparency into local medical care patterns within Little Rock, AR.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Pulmonary Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.